Society of Immunology (ASI) was formed 14 years ago and has run regular symposia and workshops in conjunction with the ASI since that time. In December 2007 the SIG-MI held a one day satellite workshop in conjunction with the annual ASI scientific meeting in Sydney to celebrate the decade since hosting the 9 th International Congress of Mucosal Immunology (9-ICMI) in 1997 which was also held in Sydney.
The Mucosal Immunology Special Interest Group (SIG-MI) of the Australasian Society of Immunology (ASI) was formed 14 years ago and has run regular symposia and workshops in conjunction with the ASI since that time. In December 2007 the SIG-MI held a one day satellite workshop in conjunction with the annual ASI scientific meeting in Sydney to celebrate the decade since hosting the 9 th International Congress of Mucosal Immunology (9-ICMI) in 1997 which was also held in Sydney.
The meeting which was attended by 65 delegates focussed on 4 session themes:
reproductive immunology, respiratory immunology, mucosal immunology of the gastrointestinal tract and mucosal vaccines.
REPRODUCTIVE IMMUNOLOGY
The plenary speaker, Professor Charles Wira (Dartmouth Hitchcock Medical Center, USA), provided an overview of how the female sex hormones estradiol and progesterone regulate both innate and adaptive immunity in the female reproductive tract to meet the unique requirements of accommodating an immunologically distinct fetus and protecting against sexually transmitted viral and bacterial pathogens. He provided evidence that innate immunity may provide the major means of protection against infection at the time of the reproductive cycle when adaptive immunity is down regulated by sex hormones to facilitate successful reproduction. The need to regulate the adaptive immune system in the female reproductive tract for successful reproduction may provide a window of vulnerability to sexually transmitted pathogens such as HIV and must also be considered when evaluating the effectiveness of vaccines against sexually transmitted pathogens where vaccine-induced responses may also be affected by sex hormone regulation.
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The use of bioinformatics approaches for in silico identification of novel protective chlamydial antigens was discussed by Professor Ken Beagley (Institute of Health and Biomedical Innovation, Queensland University of Technology, Australia).
Using two web-based T cell epitope prediction programs, chlamydial T cell epitopes that were conserved across the two major human chlamydial pathogens Chlamydia trachomatis and C. pneumoniae and that bound several MHC-II types, were identified. Immunisation of mice with one of these antigens (ribonucleotide reductase small chain protein, NrdB) elicited chlamydia-neutralising antibodies in serum and genital tract secretions. Adoptive transfer of NrdB-specific CD4 T cells to naïve mice provided partial protection against genital chlamydia infection (Barker et al. in press).
Combinations of novel antigens are currently being evaluated in animal models of chlamydial infection.
Continuing the chlamydia theme Alison Carey (Institute of Health and
Biomedical Innovation, Queensland University of Technology, Australia) reported on how the timing of chlamydial vaccination might affect the clearance of Chlamydia following a genital challenge infection. Using previously established vaccination regimes (Berry et al, 2004; Skelding et al 2006) , naïve mice, mice that had recovered from a chlamydial infection or mice that were at the peak of an ongoing genital infection were immunised with the chlamydial major outer membrane protein (MOMP) mixed with the adjuvants cholera toxin and CpG. Immunisation during an ongoing chlamydial infection did not affect recoverable chlamydial counts or rates of clearance compared to infected, non-immunised mice, however the degree of An important leukocyte compartment also occurs in the peri-arterial space in different diseases but the reason for this is not known. In studies of human lungs following fatal asthma attacks the perivascular space has many eosinophils and mast cells.
There are species differences with rats and humans, but not mice, having an arterial blood supply to the bronchial wall. The need for examination of all lung compartments containing lymphocytes when assessing allergic or pathogenic responses was emphasised.
Associate Professor Margaret Dunkley (Hunter Immunology Ltd, University of Newcastle, Australia) presented results of Phase 1 and 2 clinical studies with a killed whole-cell non-typeable Haemophilus influenzae (NTHi) oral vaccine (HI-164OV). In the 3-month Phase 1 study, smokers (10 cigarettes per day for the past two years), were administered HI-164OV or placebo tablets on days 1-3, 29-31 and 57-59. Thirty placebo and 30 active treatment subjects completed the study.
Examination of NTHi-specific lymphocytes in blood by in vitro stimulation with NTHi antigen, showed an increase throughout the study in the placebo group suggesting induction of NTHi-specific T cells as a result of exposure to live NTHi.
The HI-164OV vaccine boosted this naturally-occurring response. The serum NTHispecific IgA response fell in the placebo group and rose slightly in the active group.
The serum and saliva NTHi-specific IgG remained unchanged in the active group but was higher and more variable in the placebo group suggesting this was due to exposure to live NTHi that reached the lower airways and that this was being prevented in the active treatment group. The relationship between exposure to live NTHi and serum NTHi-specific IgG in the placebo group was further demonstrated by the fact that placebo subjects with higher exposure to NTHi (as measured by number of visits at which NTHi was detected in gargle samples) had a significant increase in NTHi-specific IgG and those without such exposure to live NTHi did not.
Efficacy of HI-164OV was indicated by a significant reduction in use of concomitant medication in the active treatment group.
In the Phase 2 studies, subjects were recruited on the basis of having 2 or more acute bronchitis episodes per year for the past 2 years and on the basis of FEV1 were allocated to Study HIH004 (Mild to moderate, FEV1 > 50% of the predicted value) or Study HIH002 (Moderate to severe, FEV1 < 50% of the predicted value). In each study, subjects were randomly allocated to receive medication or placebo. The number of subjects randomised and analysed was 38 for HI-H002 and 102 for HI-H004. These studies demonstrated that HI-164 reduces the severity of acute exacerbations, assessed by hospitalisation, and usage of medication (antibiotics, steroids, bronchodilators). Subjects with moderate to severe COPD had particular benefit compared to those with mild airway disease and a major reduction in hospitalisation (of 90%) due to respiratory events seen in the moderate-severe disease group, identifies oral immunisation with HI-164OV as a distinctive novel therapy for patients with COPD.
Mechanisms of airway hyper-responsiveness (AHR) were also addressed in but the conclusions from these studies were that allergic sensitization increased antigen uptake and processing, and was mediated by specific antibody because the activity was antigen-specific and could be transferred to naïve mice by serum transfer.
IgG1 appears to be responsible for enhanced antigen uptake in this model since a role for IgE was ruled out when heat-inactivation had no effect on opsonisation. 
MUCOSAL IMMUNOLOGY OF THE GASTROINTESTINAL TRACT

Innate defences
Recent years have seen considerable advances in our understanding of the induction and regulation of inflammatory responses to pathogenic infection of the gastrointestinal mucosa. In particular, the major contribution of the innate immune system in these processes was only relatively recently fully appreciated. For example, Nod1, a cytoplasmic molecule which recognises peptidoglycan from pathogenic Gram negative bacteria, is now recognised as an important mediator of inflammation. While Ghrelin is an immunomodulatory hormone produced by enteroendocrine cells of the gastric mucosa which was recently recognised as possessing anti-inflammatory activity. For example, in mouse models it has been shown to suppress pancreatitis, arthritis and accelerate the healing of gastric ulcers. It can also ameliorate dextran sodium sulfate (DSS) induced colitis. These activities may be due to inhibition of the production of proinflammatory cytokines, possibly by inhibition of NFκB activation.
Multiple peptides with differing activities can be derived from the ghrelin gene.
Penny Jeffery investigated the therapeutic activity of these peptides using the 5% DSS model of colitis and found that one, the Δ4 proghrelin peptide, prevented colon lengthening and weight loss in murine DSS colitis, similar to ghrelin itself, although these anti-inflammatory effects appeared to be limited to the proximal colon. The Δ4 peptide was demonstrated to significantly increase IL-10 and CCR4 mRNA expression while having no effect on pro-inflammatory cytokines such as IL-1ß and IL-12. In addition, expression of FOXP3 and PPARγ (essential for Treg mediated protection against colitis) in Tregs and colon extracts respectively was considerably increased by treatment with Δ4 peptide. Hence the Δ4 proghrelin peptide appears to have potential for the treatment of colitis, with benefit possibly being derived by the enhancement of mucosal tolerance via Treg activity. (Bourges et al., 2007) . Lesser proliferative effects were observed in the spleens and brachial lymph nodes of mice receiving anti-MAdCAM-1 ovalbumin, demonstrating a targeted response in mucosal lymphoid tissues. The induction of these antigen-specific CD8+ cells required the presence of dendritic cells as when similar injections were performed in mice depleted of DCs, the CD8 response was considerably ablated. This suggests that ovalbumin delivered to mesenteric lymph nodes by an anti-MAdCAM antibody is crosspresented to CD8 cells by dendritic cells, although the pathway by which the antigen passes from the high endothelial venule surface to dendritic cells contained within the lymph nodes remains to be determined. Importantly, however, these cells had CTL activity, as demonstrated both by an in vitro lysis assay and, most notably, by the induction of protection against subsequent challenge with an OVA expressing tumour.
Induction of CD8 T cell responses
MUCOSAL VACCINES
The middle ear
The middle ear can be regarded as a mucosal site. It is lined by a mucosa that is a continuum of that of the nasopharynx and responds immunologically similarly to that observed at other mucosal sites (Kurono & Mogi, 1996) . Infective agents track into the normally middle ear space via the Eustachian tube to cause infection. The major bacterial pathogens that cause OM are S. pneumoniae, NTHi and M. catarrhalis and there is a correlation between colonisation and concurrent infection with these microbes (Faden et al 1990) . There is a paucity of information concerning the immunology of the middle ear and response to infection at this site and further studies are required. Professor Jennelle Kyd (Central Queensland University, Australia) reviewed the preclinical animal model data which indicate that vaccination is a feasible intervention to prevent infection of the middle ear. A number of vaccine antigens have been identified and require human trials (Kyd et al 2003; Cripps et al 2005; Cripps & Otczyk 2006) .
Vaccination against influenzae H5N1
The pathogenesis of H5N1 influenzae and potential risk of a major influenzae pandemic was reviewed by Dr Ian Barr (CSL Ltd, Victoria, Australia). There is no pre-existing humoral immunity to H5 in the human population. The major reasons for the severity of disease following infection include the overwhelming inflammatory host response and ability of the virus to rapidly replicate to high titres. Three pylori. This technology has previously been explored to target PLGA nanoparticles (Gupta et al 2006) . Following oral immunization of mice with agglutinated bacteria, significantly raised levels of both IgG and IgA specific H. pylori antibody was observed in serum, intestinal mucous and vaginal washings. However, accelerated clearance of H. pylori infection was not observed. The studies were extended to Campylobacter jejuni and a similar enhancement of serum and intestinal IgG and IgA specific C. jejuni antibodies to that observed for H. pylori was observed. However, in contrast to H. pylori an enhanced clearance of the C. jejuni infection was observed.
The specific targeting of vaccines to M cells is a promising strategy for mucosal immunisation. Further research is required using lectins such as UEA-1 to optimise this approach and eventually to undertake human studies.
CONCLUDING REMARKS
Australia has over the last century made a significant contribution to immunology and infectious diseases with three of her citizens being awarded a Nobel Prize for their outstanding and innovative research. Australian scientists have also made major contributions, over again a long period of time, to our understanding of the interaction between the mucosal immune surface and infective and environmental as well as reproductive events. This research has had widespread applications to both human health and the veterinary industry. This Workshop report provides a very brief overview of some of the mucosal immunology research that is currently being undertaken in 12 organisations across Australia. Areas of research included the respiratory tract and middle ear, the reproductive tract and the gastrointestinal tract.
Presentations also covered fundamental immunological mechanistic studies and vaccine applications. The presentations were given by 2 internationally renowned mucosal immunologists, leading Australian mucosal immunologists and most importantly a number of early career researchers. Mucosal immunology down-under remains an area of great research activity a decade after 9-ICMI.
